Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Zhongguo Fei Ai Za Zhi ; 26(2): 148-150, 2023 Feb 20.
Article in Chinese | MEDLINE | ID: covidwho-2268854

ABSTRACT

In recent years, the corona virus disease 2019 (COVID-19) pandemic has had a huge impact on the global medical, political and economic fields. Since the beginning of the COVID-19 epidemic, our understanding of the impact of COVID-19 has grown exponentially. Recently, the COVID-19 epidemic has changed rapidly in China, and there has been controversy over how to carry out surgical operations for patients with lung neoplastic lesions. Some studies have shown that lung cancer patients undergoing surgery are more likely to experience respiratory failure and perioperative death after contracting COVID-19 than the general population, however, delays in cancer treatment are also associated with increased mortality among these patients. In particular, the novel coronavirus Omikron variant has a higher transmissibility and may escape the immunity obtained through the previous novel coronavirus infection and vaccination. In order to minimize the risk of novel coronavirus infection in surgical patients, it is necessary to develop new treatment guidelines, expert consensus and preventive measures. However, the current rapid change of the epidemic situation has led to insufficient time and evidence to develop guidelines and consensus. Therefore, thoracic surgeons need to evaluate specific patient populations at higher risk of severe complications before surgery and weigh the benefit of surgical treatment against the risk of novel coronavirus infection. We try to give some recommendations on lung surgery during the current domestic epidemic situation based on the guidelines and consensus of oncology and thoracic surgery organizations in different regions on lung surgery.
.


Subject(s)
COVID-19 , Lung Neoplasms , Multiple Pulmonary Nodules , Humans , Lung Neoplasms/complications , SARS-CoV-2 , Pandemics/prevention & control , Lung
2.
Smart Health (Amst) ; 26: 100348, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2069689

ABSTRACT

COVID-19 has become a matter of serious concern over the last few years. It has adversely affected numerous people around the globe and has led to the loss of billions of dollars of business capital. In this paper, we propose a novel Spatial-Temporal Synchronous Graph Transformer network (STSGT) to capture the complex spatial and temporal dependency of the COVID-19 time series data and forecast the future status of an evolving pandemic. The layers of STSGT combine the graph convolution network (GCN) with the self-attention mechanism of transformers on a synchronous spatial-temporal graph to capture the dynamically changing pattern of the COVID time series. The spatial-temporal synchronous graph simultaneously captures the spatial and temporal dependencies between the vertices of the graph at a given and subsequent time-steps, which helps capture the heterogeneity in the time series and improve the forecasting accuracy. Our extensive experiments on two publicly available real-world COVID-19 time series datasets demonstrate that STSGT significantly outperforms state-of-the-art algorithms that were designed for spatial-temporal forecasting tasks. Specifically, on average over a 12-day horizon, we observe a potential improvement of 12.19% and 3.42% in Mean Absolute Error (MAE) over the next best algorithm while forecasting the daily infected and death cases respectively for the 50 states of US and Washington, D.C. Additionally, STSGT also outperformed others when forecasting the daily infected cases at the state level, e.g., for all the counties in the State of Michigan. The code and models are publicly available at https://github.com/soumbane/STSGT.

4.
Sustainability ; 14(11):6645, 2022.
Article in English | ProQuest Central | ID: covidwho-1892972

ABSTRACT

In the face of demand disruptions, dual-channel supply chains (SCs) that lack resilience may be more vulnerable. Reaching moderate SC resilience through coordination is essential for dealing with disruptions. This paper investigates the operation management of a dual-channel fresh-food SC (FSC) under disruption. The centralized and decentralized decision models propose joint quality efforts based on the consideration of quality preference and loss. From the perspective of SC resilience, we analyze how SC members can optimally make price, quality, and quantity decisions resiliently and robustly under the disruption of quality preference. The results show that (1) no matter the kind of decision model, considering quality preference disruptions can significantly increase the SC profit;(2) there is a resilience range in decisions with the influence of the disruption cost. The original optimal decisions in the resilience range are robust and sustain SC performance without change;and (3) the disruption significantly impacts offline channel retailers, who are at a disadvantage when competing with online channels. A centralized decision model can achieve higher profits and quality levels in response to demand disruptions. This paper extends the concept of resilience to the FSC and provides suggestions for fresh-food enterprises to conduct quality efforts and cope with demand interruption.

5.
Sci Transl Med ; 14(632): eabi5735, 2022 Feb 16.
Article in English | MEDLINE | ID: covidwho-1691438

ABSTRACT

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019 (COVID-19). We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50 µg) SpFN vaccine, given twice 28 days apart, induced a Th1-biased CD4 T cell helper response and elicited neutralizing antibodies against SARS-CoV-2 wild-type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates following high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates supports the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.


Subject(s)
COVID-19 , Nanoparticles , Animals , Antibodies, Neutralizing , Antibodies, Viral , COVID-19 Vaccines , Ferritins , Humans , Immunity , Macaca mulatta , SARS-CoV-2 , Spike Glycoprotein, Coronavirus
6.
NPJ Vaccines ; 6(1): 129, 2021 Oct 28.
Article in English | MEDLINE | ID: covidwho-1493109

ABSTRACT

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 µg) or low (0.2 µg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

7.
Biosens Bioelectron ; 197: 113759, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1487617

ABSTRACT

The current pandemic of COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) has raised significant public health concerns. Rapid and accurate testing of SARS-CoV-2 is urgently needed for early detection and control of the disease spread. Here, we present an RT-LAMP coupled glass nanopore digital counting method for rapid detection of SARS-CoV-2. We validated and compared two one-pot RT-LAMP assays targeting nucleocapsid (N) and envelop (E) genes. The nucleocapsid assay was adopted due to its quick time to positive and better copy number sensitivity. For qualitative positive/negative classification of a testing sample, we used the glass nanopore to digitally count the RT-LAMP amplicons and benchmarked the event rate with a threshold. Due to its intrinsic single molecule sensitivity, nanopore sensors could capture the amplification dynamics more rapidly (quick time to positive). We validated our RT-LAMP coupled glass nanopore digital counting method for SARS-CoV-2 detection by using both spiked saliva samples and COVID-19 clinical nasopharyngeal swab samples. The results obtained showed excellent agreement with the gold standard RT-PCR assay. With its integration capability, the electronic nanopore digital counting platform has significant potential to provide a rapid, sensitive, and specific point-of-care assay for SARS-CoV-2.


Subject(s)
Biosensing Techniques , COVID-19 , Nanopores , Humans , Molecular Diagnostic Techniques , Nucleic Acid Amplification Techniques , RNA, Viral , SARS-CoV-2 , Sensitivity and Specificity
8.
Matern Fetal Med ; 2(2): 68-71, 2020 Apr.
Article in English | MEDLINE | ID: covidwho-1410267

ABSTRACT

Since the outbreak of the novel coronavirus in Wuhan, China, as obstetricians, we also face great challenges. We need to identify pregnant patients with 2019 coronavirus disease infection timely, and give them appropriate treatment in order to obtain a good maternal and infant prognosis. Here, we would like to share a case and provide some suggestions on how to screen, diagnose and treat pregnant women with 2019 coronavirus disease infection during the outbreak.

9.
Proc Natl Acad Sci U S A ; 118(38)2021 09 21.
Article in English | MEDLINE | ID: covidwho-1392996

ABSTRACT

Emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for next-generation vaccines able to elicit broad and durable immunity. Here we report the evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ). RFN vaccination of macaques using a two-dose regimen resulted in robust, predominantly Th1 CD4+ T cell responses and reciprocal peak mean serum neutralizing antibody titers of 14,000 to 21,000. Rapid control of viral replication was achieved in the upper and lower airways of animals after high-dose SARS-CoV-2 respiratory challenge, with undetectable replication within 4 d in seven of eight animals receiving 50 µg of RFN. Cross-neutralization activity against SARS-CoV-2 variant B.1.351 decreased only approximately twofold relative to WA1/2020. In addition, neutralizing, effector antibody and cellular responses targeted the heterotypic SARS-CoV-1, highlighting the broad immunogenicity of RFN-ALFQ for SARS-CoV-like Sarbecovirus vaccine development.


Subject(s)
COVID-19 Vaccines/administration & dosage , COVID-19/virology , Macaca mulatta/immunology , Nanoparticles/chemistry , Receptors, Virus/metabolism , SARS-CoV-2/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Neutralizing/biosynthesis , Antibodies, Neutralizing/immunology , Antibodies, Viral/biosynthesis , Antibodies, Viral/immunology , COVID-19/prevention & control , COVID-19 Vaccines/immunology , Ferritins/chemistry , SARS-CoV-2/metabolism , T-Lymphocytes/immunology
10.
Zhongguo Fei Ai Za Zhi ; 23(3): 133-135, 2020 03 20.
Article in Chinese | MEDLINE | ID: covidwho-1389585

ABSTRACT

In December 2019, China diagnosed the first patient with 2019 novel coronavirus disease (COVID-19), and the following development of the epidemic had a huge impact on China and the whole world. For patients with lung occupying lesions, the whole process of diagnosis and treatment can not be carried out as usual due to the epidemic. For thoracic surgeons, the timing of surgical intervention should be very carefully considered. All thoracic surgeons in China should work together to develop the proper procedures for the diagnosis and treatment in this special situation, and continuously update the recommendations based on epidemic changes and further understanding of COVID-19. Here, we only offer some preliminary suggestions based on our own knowledge for further reference and discussion.


Subject(s)
Betacoronavirus , Coronavirus Infections , Lung Diseases , Pneumonia, Viral , Thoracic Surgical Procedures , Betacoronavirus/pathogenicity , COVID-19 , China/epidemiology , Epidemics , Humans , Lung Diseases/diagnosis , Lung Diseases/surgery , Patient Care Planning , SARS-CoV-2
11.
Cells ; 10(3)2021 03 12.
Article in English | MEDLINE | ID: covidwho-1167427

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the global pandemic of coronavirus disease 2019 (COVID-19) and particularly exhibits severe symptoms and mortality in elderly individuals. Mounting evidence shows that the characteristics of the age-related clinical severity of COVID-19 are attributed to insufficient antiviral immune function and excessive self-damaging immune reaction, involving T cell immunity and associated with pre-existing basal inflammation in the elderly. Age-related changes to T cell immunosenescence is characterized by not only restricted T cell receptor (TCR) repertoire diversity, accumulation of exhausted and/or senescent memory T cells, but also by increased self-reactive T cell- and innate immune cell-induced chronic inflammation, and accumulated and functionally enhanced polyclonal regulatory T (Treg) cells. Many of these changes can be traced back to age-related thymic involution/degeneration. How these changes contribute to differences in COVID-19 disease severity between young and aged patients is an urgent area of investigation. Therefore, we attempt to connect various clues in this field by reviewing and discussing recent research on the role of the thymus and T cells in COVID-19 immunity during aging (a synergistic effect of diminished responses to pathogens and enhanced responses to self) impacting age-related clinical severity of COVID-19. We also address potential combinational strategies to rejuvenate multiple aging-impacted immune system checkpoints by revival of aged thymic function, boosting peripheral T cell responses, and alleviating chronic, basal inflammation to improve the efficiency of anti-SARS-CoV-2 immunity and vaccination in the elderly.


Subject(s)
COVID-19/immunology , Cellular Senescence/immunology , T-Lymphocytes/immunology , Thymus Gland/immunology , Aged , Aged, 80 and over , Aging/immunology , Aging/pathology , Autoimmunity , COVID-19/physiopathology , Humans , Inflammation/immunology , Inflammation/pathology , SARS-CoV-2/immunology , Thymus Gland/drug effects , Thymus Gland/physiopathology , Thymus Gland/virology , COVID-19 Drug Treatment
12.
Biosens Bioelectron ; 178: 113012, 2021 Apr 15.
Article in English | MEDLINE | ID: covidwho-1039298

ABSTRACT

The current pandemic of the 2019 novel coronavirus (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) has raised significant public health concern. Rapid, affordable, and accurate diagnostics of SARS-CoV-2 is essential for early treatment and control of the disease spread. In the past few years, CRISPR technology has shown great potential for highly sensitive and specific molecular diagnostics. Amid the ongoing COVID-19 pandemic, there is an increasing interest in implementing CRISPR-based diagnostic principles to develop fast and precise methods for detecting SARS-CoV-2. In this work, we reviewed and summarized these CRISPR-based diagnostic systems as well as their characteristics and challenges. We also provided future perspectives of CRISPR-based sensing towards point-of-care molecular diagnosis applications.


Subject(s)
COVID-19 Nucleic Acid Testing/methods , COVID-19/diagnosis , CRISPR-Cas Systems , Bacterial Proteins/genetics , Biosensing Techniques/methods , Biosensing Techniques/trends , COVID-19/virology , COVID-19 Nucleic Acid Testing/trends , CRISPR-Associated Proteins/genetics , CRISPR-Cas Systems/genetics , Endodeoxyribonucleases/genetics , Humans , Molecular Diagnostic Techniques/methods , Molecular Diagnostic Techniques/trends , Pandemics , Point-of-Care Testing/trends , RNA, Viral/genetics , RNA, Viral/isolation & purification , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Workflow
13.
Comput Struct Biotechnol J ; 19: 161-167, 2021.
Article in English | MEDLINE | ID: covidwho-978253

ABSTRACT

The SARS-CoV-2 virus and its homolog SARS-CoV penetrate human cells by binding of viral spike protein and human angiotensin converting enzyme II (ACE2). SARS-CoV causes high fever in almost all patients, while SARS-CoV-2 does not. Moreover, analysis of the clinical data revealed that the higher body temperature is a protective factor in COVID-19 patients, making us to hypothesize a temperature-dependent binding affinity of SARS-CoV-2 to human ACE2 receptor. In this study, our molecular dynamics simulation and protein surface plasmon resonance cohesively proved the SARS-CoV-2-ACE2 binding was less affinitive and stable under 40 °C (~18 nM) than the optimum temperature 37 °C (6.2 nM), while SARS-CoV-ACE2 binding was not (6.4 nM vs. 8.5 nM), which evidenced the temperature-dependent affinity and explained that higher temperature is related to better clinical outcome. The decreased infection at higher temperature was also validated by pseudovirus entry assay using Vero and Caco-2 cells. We also demonstrated the structural basis of the distinct temperature-dependence of the two coronaviruses. Furthermore, the meta-analysis revealed a milder inflammatory response happened in the early stage of COVID-19, which explained the low fever tendency of COVID-19 and indicated the co-evolution of the viral protein structure and the inflammatory response. The temperature dependence of the binding affinity also indicated that higher body temperature at early stages might be beneficial to the COVID-19 patients.

14.
Pathog Dis ; 78(4)2020 06 01.
Article in English | MEDLINE | ID: covidwho-616775

ABSTRACT

The evidence of long-term clinical dynamic on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA re-positive case are less. We performed a 108 days follow-up on dynamic clinical presentations in a case, who hospitalized three times due to the positive recurrence of SARS-CoV-2 RNA after discharge, to understand the prognosis of the 2019-Coronavirus disease (COVID-19). In this case, positive SARS-CoV-2 recurred even after apparent recovery (normal CT imaging, no clinical symptoms, negative SARS-CoV-2 on stool sample and negative serum IgM test) from COVID-19, viral shedding duration lasted for 65 days, the time from symptom onset to disappearance was up to 95 days. Erythrocyte-associated indicators, liver function and serum lipid metabolism presented abnormal throughout during the observation period. Awareness of atypical presentations such as this one is important to prompt the improvement of the management of COVID-19.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/blood , Coronavirus Infections/virology , Pneumonia, Viral/blood , Pneumonia, Viral/virology , RNA, Viral/genetics , Virus Shedding , Adult , Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Aspartate Aminotransferases/blood , Betacoronavirus/drug effects , Betacoronavirus/genetics , Biomarkers/blood , COVID-19 , Cholesterol, HDL/blood , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/drug therapy , Hospitalization , Humans , Interferon alpha-2/therapeutic use , Lopinavir/therapeutic use , Male , Methylprednisolone/therapeutic use , Pandemics , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/drug therapy , RNA, Viral/isolation & purification , Recurrence , SARS-CoV-2 , Tomography, X-Ray Computed , gamma-Glutamyltransferase/blood
17.
ssrn; 2020.
Preprint in English | PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3561379

ABSTRACT

The rapid spread of COVID-19 results in a pandemic throughout the world, however, there are currently no specific treatments available. We report the first case of ozonated autohemotherapy for a critically ill patient with COVID-19. The patient was diagnosed with severe acute respiratory distress syndrome (ARDS) and life-threatening refractory hypoxemia within 72 hours of the intensive-care unit (ICU) admission. To improve the oxygen delivery, the ozonated autohemotherapy was performed with 40 µg/ml of ozone in 100 ml of blood for 5 days on this patient, who then recovered from ARDS uneventfully and discharged from hospital after viral clearance. This case suggests ozonated autohemotherapy might be an alternative non-invasive medical treatment for critically ill COVID-19 patients.


Subject(s)
COVID-19 , Hypoxia , Respiratory Distress Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL